Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Farlow

Showing results (1-10 of 111) with videos related to

Pageof 12
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 11, 1998
Etiology and pathogenesis of Alzheimer's diseaseM R Farlow
Neurology|May 1, 1997
Alzheimer's disease: clinical implications of the apolipoprotein E genotypeM R Farlow
International Journal of Clinical Practice. Supplement|July 26, 2002
Do cholinesterase inhibitors slow progression of Alzheimer's disease?M R Farlow
Archives of Neurology|November 21, 1998
New treatments in Alzheimer disease and the continued need for placebo-controlled trialsM R Farlow
Current Alzheimer Research|August 20, 2009
Treatment of mild cognitive impairment (MCI)M R Farlow
International Journal of Clinical Practice. Supplement|July 26, 2002
Cholinesterase inhibitors: relating pharmacological properties to clinical profiles: IntroductionM R Farlow
Clinical Therapeutics|June 9, 2001
Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamineM R Farlow
Dementia and Geriatric Cognitive Disorders|June 27, 2000
Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trialsM R Farlow, P A Cyrus
Journal of Molecular Neuroscience : MN|January 1, 1996
Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell linesD K Lahiri, M R Farlow
Expert Opinion on Pharmacotherapy|February 5, 2002
New concepts in the drug therapy of Alzheimer's diseaseA M Hake, M R Farlow
Pageof 12

Showing results (1-10 of 111) with videos related to

Sort By:
Pageof 12
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 11, 1998
Etiology and pathogenesis of Alzheimer's diseaseM R Farlow
Neurology|May 1, 1997
Alzheimer's disease: clinical implications of the apolipoprotein E genotypeM R Farlow
International Journal of Clinical Practice. Supplement|July 26, 2002
Do cholinesterase inhibitors slow progression of Alzheimer's disease?M R Farlow
Archives of Neurology|November 21, 1998
New treatments in Alzheimer disease and the continued need for placebo-controlled trialsM R Farlow
Current Alzheimer Research|August 20, 2009
Treatment of mild cognitive impairment (MCI)M R Farlow
International Journal of Clinical Practice. Supplement|July 26, 2002
Cholinesterase inhibitors: relating pharmacological properties to clinical profiles: IntroductionM R Farlow
Clinical Therapeutics|June 9, 2001
Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamineM R Farlow
Dementia and Geriatric Cognitive Disorders|June 27, 2000
Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trialsM R Farlow, P A Cyrus
Journal of Molecular Neuroscience : MN|January 1, 1996
Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell linesD K Lahiri, M R Farlow
Expert Opinion on Pharmacotherapy|February 5, 2002
New concepts in the drug therapy of Alzheimer's diseaseA M Hake, M R Farlow
Pageof 12